text:
sofrigam-logo
sofrigam
Sofrigam ensures the delivery of your orders trhou...
Sofrigam sponsor of the GIRP Supply Chain conferen...
Design of a labelled cooling pouch for the transpo...
UN3373 insulated packaging to secure the shipment ...
Thematic studies
Stabilisation protocols for eutectic plates
Qualification standards for insulated packaging
Thermochemical sorption: a solution for temperatur...
Sofrigam Group, the specialist in temperature-cont...
An innovative, efficient and environmentally-frien...
Sofrigam strengthens its offer with Coldway Techno...
Studies and news on the pharmaceutical cold chain > News
Transporting medicines by air: how to reduce costs?
Boxes for vaccinations, cancer drugs, insulin pens, etc.: an increasing share of the pharmaceutical products sent by air cargo need to be kept within an exact temperature range. And this is likely to continue! What are the challenges of air transportation for these heat-sensitive medicines? How can it be optimized? We will advise you.
Transportation of medicines by air
Maintain the integrity of the cold chain despite the significant constraints
Never break the cold chain of sensitive medicines, this is the primary constraint when transporting medicines. This involves keeping the product at a constant temperature throughout transportation, which includes the storage stages and various transfers. Air cargo can be a real challenge and the biggest obstacles are transit.
Whatever the logistical circuit, the packaging solution will pass through both open and closed segments. As such, it is subjected to temperature fluctuations which can be significant. For example, the package will pass over the airport tarmac (open segment) and be subjected to a temperature of more than +30°C then transit through customs (closed segment) where the temperature is +20°C to then be stored in a temperature-controlled area at +5°C. The wide range of temperatures encountered in this circuit requires a reliable method for storing heat-sensitive products within the required temperature range.
Optimize the air transportation costs of medicines: some tips
Although air cargo has the advantage of being a fast means of transport and today perfectly adapted to shipments via the cold chain, it is a costly and environmentally unfriendly mode of transport.
Here are a few tricks to help reduce air transportation costs of heat-sensitive medicines and minimize your carbon footprint at the same time, while ensuring perfect control of the cold chain:
First, clearly define your actual needs according to your logistical circuit to avoid using a solution with a greater efficiency than your actual needs. The solution will be more expensive to purchase, loaded with more eutectic plates and as such heavier and offer a smaller payload.
Maximize the loading rate of the insulated packaging solution to transport more medicines in one shipment.
Aim to choose a packaging solution which offers a very good external size ratio/payload (an efficient packaging solution is not overloaded with eutectic plates).
Check if the packaging solution has internal fixtures to facilitate loading and therefore save time.
Use an insulated packaging solution adapted to the size of cargo platforms for shipments of large volumes of medicines.
Lastly, for complex logistical circuits or specific requirements, consider the possibility of designing a customized packaging solution. You will then have a packaging solution optimized for your shipments and perfectly adapted to your constraints.
"Initial" pallet shipper: a packaging solution designed for air cargo
Pallet Shipper: refrigerated container designed for air cargo
The Pallet Shipper was created by Sofrigam 15 years ago to respond to the needs of transportation via the cold chain for one of the leaders of the pharmaceutical sector. It quickly emerged as a packaging beacon for transporting heat-sensitive medicines by plane.
This is a completely autonomous packaging solution which stores fresh pharmaceutical products (+2/+8°C), at a controlled room temperature (+15/+25°C) or frozen (-18°C). With an internal volume of more than 1 900 litres, the container can directly accommodate a European or US pallet. The pallet shipper is then loaded in one go: saving a tremendous amount of time on loading! The internal configurations have been examined to facilitate the loading of eutectic plates and allow an even temperature within the packaging solution.
Lastly, its XXL size is perfectly optimized: the pallet shipper occupies a quarter of an air cargo platform, in such a way as to use all the space available for shipping your products.
Your load remains at a constant temperature for up to 120 hours, with no risk of breaking the cold chain.
The challenges of transporting heat-sensitive medicines by plane are significant. Nevertheless, good management of the cold chain and the correct choice of insulated packaging solution will help to control and optimize specific aspects.
Sofrigam Group
Sofrigam LinkedIn Sofrigam YouTube Sofrigam Twitter
Coldway Technologies
ColdShop
Ater Metrology
Competence Certificate – examining the impartiality and the independence of a certifying body, according to the norms in force. Through accreditation, an authoritative body formally recognises that an organisation or individual is competent to carry out certain tasks. Accreditation establishes a large degree of confidence in the body's ability to issue certifications, representing confirmation from the relevant organisation. The certificates, delivered by those accredited to do so, are thereby endowed with complete trust and credibility on the market.
Active container
Crate or insulated container equipped with the Coldway Inside° refrigeration production system (usually in the upper part).
Active roll
Insulated mobile crate equipped with Coldway Inside° refrigeration system (in its lower part).
Good Distribution Practice of medicinal products (GDP)
The title of this regulatory reference is: 'Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use' (2013/C 343/01). This document is issued by the institutions, bodies and organisations from within the European Union. It fixes the rules in respect of the distribution of medication (storage, transport, sub-contracting, etc.).
CertiCold Pharma
CertiCold is a quality label for cold chain products delivered on the basis of private technical specifications and established in conjunction with the relevant manufacturers and the professional users. The label CertiCold Pharma relates to cold chain equipment for health products – for packaging solutions for the transportation of health products and for transport units under controlled temperature for health products.
Procedure by which a third part gives written assurance that a product, process or service conforms to specified requirements.
This is the full method used to maintain a product at a constant temperature throughout the transport process, all the way to its final destination.
Coldway Inside°
An autonomous, active refrigeration system using the technology patented by Coldway Technologies. The Rolls and active Containers are all equipped with this technology, facilitating constant and controlled refrigeration which is both silent and de-carbonised.
This is a measuring device which records and stores temperature readings. It is equipped with a temperature probe, memory storage, a display system and alarms. Some recorders can also communicate the results in real-time.
Isothermal packaging
Packaging case (or box or container) comprising of a thermal insulation on each wall to reduce heat exchange with the environment.
Refrigerated Packaging
Insulated box equipped with a refrigeration source (refrigeration accumulators). The refrigeration source may be eutectic plates or phase-change materials (PCM) or even dry-ice.
End-to-End Logistics
The pharmaceutical supply chain from start to finish, or End-to-End, involves the logistical operations of transporting and storing medication, from the manufacturing site to delivery at the health facilities such as clinics, hospitals, and dispensaries – and in some cases even to the patient himself.
Eutectic plates
The eutectic plates are water-based thermic accumulators (for cold or heat). The aqueous solution facilitates the stocking of thermic energy in the solid or liquid sensitive phase and by the changing of the solid/liquid phase. With fusion temperatures below or equal to 0 °C, the eutectic plates permit the maintenance of temperature differences between +2/+8 °C, under -5 °C, under -15 °C, under -18 °C or even under -20 °C.
Thermal inertia
A characteristic of a material represents its aptitude to accumulate a greater or lesser amount of heat for a given variation in temperature. The thermal inertia of a material depends on its density, thermal conductivity and mass heat.
This material is characterised by its low thermal conductivity. The most commonly used insulating materials in the manufacture of isothermal packaging are: -	Polystyrene – the traditional thermal insulator whose thermal conductivity varies between 0.03 and 0.045 W.m-1.K-1. There are two notable versions: expanded polystyrene and extruded polystyrene. -	Polyurethane – is the best classical thermal insulator. Its thermal conductivity varies between 0.02 and 0.025 W.m-1.K-1. -	Vacuum Insulated Panels (VIP) – a super-insulator in the form of vacuum panels.
This is the last stage in the logistics journey, culminating in the final destination. Health professionals and patients are an integral part of that last mile logistics.
"A document established by consensus and approved by a recognised organisation, that contains – for common and repeated use – regulations, directives or characteristics for activities (or their results) guaranteeing an optimal level of order in a given context" (a definition as set out by the ISO – International Organisation for Standardization – and the CEI). The norm is an indisputable standard on a given subject, suggesting technical and commercial solutions and used to simplify contractual relationships. To be considered as a norm, the document must fulfil two conditions: the means and the methods described must be reproducible, by using and conforming to the conditions indicated, and they must be recognised by all. In a general case the application of a norm is facultative but the law or regulations may render it obligatory. It may also be imposed by the principal to fulfil a contract.
Normalisation is the process by which norms are published and promoted. According to French regulations, the object of 'normalisation' is "to supply the reference documents containing solutions to technical and commercial problems concerning the products, goods and services that occur repeatedly within the relationships between economic, scientific, technical and social partners" (Decree n°84-74, 26/01/1984).
Patient-Centric Approach
A patient-centric approach is one in which the patient is placed at the very heart of the health care system. It is based on a partnership between the patient, his family and the health professional to travel on an adapted treatment pathway together. Professional expertise and patient experience – acquired little by little throughout his life – are linked as both of them learn from the patient's health and psycho-social problems, the illness itself and its implications on his lifestyle and that of his close family. This approach helps the patient to obtain self-caring skills, being able to adapt and manage his illness. through listening, monitoring and receiving support from the professionals throughout his treatment.
The phase-change materials (PCM) are materials that allow the storage of thermic energy by the solid or liquid sensitive phase and by the change in the solid/liquid phase. With fusion temperatures over or equal to 0 °C (positive), the PCMs allow the maintenance of the temperature differences between +2/+8 °C, +15/+25 °C as well as other specific temperature differences under specific hot or cold outdoor temperatures.
Temperature profile
A temperature profile simulates the variations of temperature in a logistics circuit, from the moment the packaging is loaded until it is unpacked. The temperature profiles can be cyclic and composed of segments, or remain at a constant temperature. Some standards allow for pre-determined levels, others leave the choice and the responsibility to the user and the manufacturer.
The qualification relates to equipment such as cold chain packaging. It consists in showing, in a documented manner, the aptitude of the solution to meet the specific demands using norms or specifications. It confirms the performance of the solutions in pre-defined conditions through laboratory tests.
Setpoint temperature
This is the optimum temperature to maximise and maintain healthiness and the security of the products inside an isotherm container.
This sensor contains a sensitive element to measure the temperature. A number of technologies involving temperature sensors exist. The most common are resistive probes (Pt 100 for example) and thermocouples.
This is a captor with a sensitive element which monitors temperature. Several temperature probe technologies can be seen working here; the most used are the resistive probes (such as Pt 100) and thermocouples.
Thermal stabilisation
Thermal stabilisation of a materiel is the maintenance of the temperature and its state at a predefined temperature.
Thermal stabilisation of a material is the conditioning of its temperature and its state at a predefined temperature.
TCO (Total Cost of Ownership)
This is a financial estimate covering the direct and indirect costs generated by the ownership and use of a product. For an isotherm packaging solution the calculation of the TCO will reveal the global financial impact of the solution. The purchase price is just one part of the global implementation cost, as transport, storage and preparation cost must be added – as well as conditioning and repatriation charges should the solution be reusable, After Sales Service is an additional expense to be considered, as are costs related to security risks such as loss, theft and temperature excursions.
Thermal performances test
This is a test carried out with an insulated or cooling packaging in a thermostatic case – this simulates the variations of the environmental temperature. It is then possible to qualify the thermal performance of the packaging by simulating various temperature changes in the surrounding environment. It is thus possible to qualify the case's thermal performance and to check the capacity to maintain temperature-sensitive products within a required range of temperatures for a given period and a pre-defined temperature profile.
The validation relates to the complete transport procedure using the temperature-controlled packaging boxes. It consists in verifying and confirming in a documented way that the solution functions correctly in real-time conditions.
Your privacy is our priority. Our site uses cookies for audience analysis purposes. You can accept or refuse the deposit of cookies.


This Thursday, LaGuardia Community College hosted its fifth annual Black Lives Matter Summit, to discuss the importance of activism and reform.
"We are in a desperate and problematic time in the history of this country," King said, highlighting recent hate crimes such as the Pittsburgh Synagogue shooting. The October attack was the deadliest attack on the Jewish community in the US, killing 11 people.
While speaking to the audience of college students, King discussed ways that young activists can bring about reform to combat inequality and injustice.
Acknowledging the limited access to resources, King advised other ways that the students can cause change. He shared the importance of organizing highly energized people and devising a plan.
In February, King relaunched the historic newspaper The North Star. The North Star was an abolitionist paper founded in the nineteenth century by writer Frederick Douglass. King says he faced challenges in the relaunch but he did not allow those obstacles to discourage him.
"Don't allow the possibility of failure convince you that you are not ready," he said, hoping to inspire the room of students.
Kingsborough Community College student Hilary Brown said she was inspired by this year's summit.
"Every day we see so many things wrong in this country, but we don't know how to really help," Brown said in an interview. "Being here today made me realize, I have to do more than just talk and tweet. I have to get involved.
Charles Cooper testified before the Campaign Finance Board (CFB) as he answered a long list of violations slapped on him after his unsuccessful run for a seat on the City Council two years ago.
He blamed a technology application used by his campaign and that app led to failure of transactions to be filed. He and his workers were unaware of the app's shortcomings, he said.
"If I had knew that, we would have never used that app," he said.
Cooper ran in a New York City Council district covering upper Manhattan, including Harlem. Cooper's ten alleged violations included failures to document outstanding liabilities, report transactions, demonstrate compliance with cash receipts reporting and other required actions.
In addition, he allegedly accepted contributions from corporations, accepted over the limit contributions, and had a petty cash fund greater than five hundred dollars.
The CFB held its meeting on Thursday so that Cooper could testify, answering the charges against him.
The CFB provides public funds to New York City Council candidates by using the matching funds program in which every $10 contribution from a New York City resident within the district that the candidate is running for will gain a $90 contribution for the candidate from the CFB.
Candidates taking part in a campaign are required to document their expenses and assure the CFB that candidates did not misuse funds.
Most of Cooper defenses had to do with asserted technological mishaps. He revealed that vendors such as UPS were unreliable in terms of the inaccuracy of their online tracking. When he looked for the tracking information, it had displayed the words "status not available," he said.
He also said that his campaign staff failed to provide alternative and simple filing options. "It takes a while to adapt to technology," he said.
Following Cooper's testimony, the board determined that he must pay a total penalty of $5,296.
Other candidates had been cited by the CFB. New York City Council candidate Alison Tan of Queens and Borough President candidate Everly Brown, also of Queens, did not appear at the board meeting. In the races two years ago, both candidates lost.
The board determined that they had committed violations and assessed penalties for those violations. The candidates will be required to pay those penalties, which amounts to $715 in total for Tan and $6,725 for Brown.
The New York City Council's Committee on Environmental Protection held a hearing at City Hall on Thursday to vote on an agenda focusing on changing the New York City building and administrative codes in order to cut down on emissions.
The committee has been working with building owners, architects, building experts and climate scientists for at least the last two years to come up with solutions in order to assist buildings in going green. This is not including the work that began with the passing of green laws as far back as a decade ago. Through their research, they've found that buildings account for approximately 70 percent of greenhouse gas emissions.
The passing of this significant piece of legislation is the single largest carbon reduction effort in any city and will, in fact, pave the way for a twenty-first century green economy, councilmembers say.
Aside from creating good middle-class jobs for New Yorkers, the bill will take approximately one million cars off the road by 2030. It will also make for measurable decreases in nitro oxide, sulfur oxide and particulate matter that fouls the air and contributes to higher than average asthma rates. Starting with the biggest and dirtiest buildings will put the city on the path of meeting the 40 percent by 2030 (40 x 30) and 80 percent by 2050 (80 x 50) goal.
The New York State Energy Research and Development Authority (NYSERDA) has created the Property Assessed Clean Energy (PACE) Financing for building owners that will allow them a low interest loan to help cover the cost of going green. The property owner voluntarily agrees to repay the financing through a special assessment or special tax charge placed on their annual property tax bill. This provides financing for these types of improvements over time without requiring the property owner to make a large upfront investment.
PACE financing is available through the Energy Improvement Corporation's (EIC) Energize NY PACE program in participating municipalities. EIC is a local development corporation and a New York State nonprofit established specifically to assist local governments and property owners achieve long-term energy savings and/or generate renewable power for use on site.
Building owners who choose to go green will see a net gain through energy savings due to using newer, more efficient technology.
Outside of City Hall, environmental activists made their to the public. Rachel Rivera of New York Communities for Change painted a very distressing picture of what she goes through every day with her six children due to the aftermath of Hurricane Sandy. She shared a story of how she began hearing a cracking noise which led to the roof caving onto her daughter Marisol's bed.
The city's new legislation states that New York City will start phasing out use of fossil fuel power plants and allow wind turbines to be built more easily in the city. These two things alone send out strong signals in the clean energy market that New York City is ready to phase out fossil fuels and convert to a greener grid. The plan is to do it in a way to give New Yorkers flexibility as it takes into account everyone's contributions to city emissions in order to reduce building emissions.
The climate emergency the city faces is leading legislators to say no to new fossil fuel infrastructure and new pipelines that will be operational for the next 30-40 years.
The committee has an opportunity to make sure that there is a sustainable New York for generations to come.
As time came to vote, the councilmembers were all too eager.
"I proudly vote 'aye'," said Councilmember Raphael L. Espinal, Jr.
"The climate change world has impacted our black and brown families, our workers on the waterfront so this is a proud moment for my district," said Menchaca.
"Happily vote 'aye'," said Councilmember Donovan J. Richards.
Councilmember Kalman Yeger voted 'aye' on all but the unnumbered pre-considered resolution, to which he stated he was not for or against due to it not being introduced to the Council.
Councilmember Eric A. Ulrich voted 'aye' on all without any additional commentary.
The hearing adjourned with a vote of six affirmative and zero negative.
His Eminence Cardinal Timothy Dolan and Director of Public Relations of Goya Foods Rafael Toro were joined Thursday morning by Catholic Charities of the Archdiocese of New York at the annual Holy Thursday Food Distribution, providing food pantry meals at Saint Rose of Lima Church.
They were together to celebrate and to feed.
Director of PR Rafael Toro announced the donation of 300,000 pounds of food, which will provide nearly 500,000 meals to New Yorkers in need. Goya Foods has been a generous supporter of the Catholic Charities' food pantries, donating over 1.5 million pounds of food to Catholic Charities of New York since the start of its support.
"No más palabras, tengo hambre (no more words, I am hungry)," said Cardinal Dolan.
The annual Holy Thursday food distribution with Goya reaffirms Catholic Charities' partnerships with programs to provide more than 4 million meals to hungry New Yorkers. Community and parish–based food programs and pantries offer non–perishable food for families to bring home, while many locations provide hot meals on site. In 2018, Catholic Charities received 600,000 pounds of food, half of which Goya donated, translating to nearly 1 million meals that were re–distributed to their partner programs.
The confetti flew high at the theater at Madison Square Garden Thursday morning, as the NYPD held its spring 2019 graduation ceremony bringing 457 new officers onto the force.
In this class, 47 are military veterans. It is the biggest class since last July, when 726 graduates entered the department.
These new officers are joining the New York City Police Department at a time when, according to Mayor Bill de Blasio, the crime rate is the lowest since the 1950's.
"The last time the crime rate was this low, the Dodgers were playing at Ebbets Field," de Blasio said.
Both the mayor and commissioner stated impactful the work of police officers is to the city. O'Neil sought to sooth the spirits of civil servants who will have difficult experiences ahead of them, and to make them happy and proud.
"You will have some bad days, truthfully, but you will have many more good than bad days," O'Neil said.
Class valedictorian Christopher Messina, who is a fourth generation NYPD officer and among 124 officers who have family members in the department, gave thanks to his father who was his main reason he decided to pursue the NYPD.
The future of flight in New York and New Jersey is a bright one, according to Port Authority Executive Director Richard Cotton.
On Thursday, Cotton issued an official progress report of the Port Authority's project to renovate the city's airports and usher them into the twenty-first century.
"Today's discussion is not about planning, it's about moving forward," said Cotton, as he revealed the major renovations coming to the major New York and New Jersey airports.
As for the airport itself, Cotton presented photos of a brand new concourse at Terminal B. The new concourse will be 250,000 square feet, hold 18 gates, as well as various concessions, and two airline lounges.
As for JFK, that historic airport has fallen on hard times in recent years, its once high reputation having diminished quite a bit, according to Cotton.
In order to make that happen, JFK will finally make use of one of its long abandoned terminals. The TWA flight center was opened in 1962, but closed in 2001 because it could not support the size of modern aircrafts. Although the terminal got stuck in time, it will not stay that way for long, according to Cotton. Cotton spoke at an event hosted by the Association for a Better New York, held at The Mezzanine, on Broadway in Manhattan.
The Port Authority on Thursday revealed images for the TWA hotel, which is set to open on May 15. Not only will the new hotel increase public interest, but several changes to outdated terminals within the airport will increase productivity.
"These changes will increase JFK's capacity by 15 million passengers," Cotton said.
In New Jersey, Newark International airport is also due for a face lift, as three new terminals are planned to be added by 2022.
Although the major airports were the focal points of Thursday's presentation, Cotton emphasized that the Port Authority is looking to improve more than just the airports. He said he wanted to transform the entire travel experience. A new emphasis on the customer experience includes free and fast WiFi, family friendly services and amenities, and even food delivery directly to airport gates.
After a presentation of groundbreaking innovations, Cotton reaffirmed the Port Authority's primary ambition.
The bright and colorful Channel Garden brightens the surrounding area, even on a gloomy day like Thursday at Rockefeller Center. The tourist attraction has a new installation for Easter, a 20-foot bird's nest and large blue eggs that children can go inside and play with.
The section is small with amazingly green soft grass and gold birds over the nest, adding to the beautiful scenery. Although it's surrounded by buildings and stores, the garden still brings a sense of peace and nature for those wanting to escape reality for a moment.
The unique and beautiful garden is part of a tradition of celebrating Easter in the biggest and brightest way possible. Every season, the garden displays exotic plants with gushy designs. The garden brings tons of tourists adding it to the list of many things they have seen in the Big Apple.
A family of four from Brazil stood around on Thursday morning with their professional-looking camera, taking pictures of their children playing on the life-size eggs. Although there was a bit of a language barrier, the mother (Rauma) was able to give her opinion to this English-speaking reporter.
Rockefeller Center was created by John D. Rockefeller (1839 – 1937), the founder of Standard Oil. He was the richest man in American during his era and he wanted to create a "city within a city," which was Rockefeller Center. By 1940, the Channel Garden came into Rockefeller Center and it became a place where New Yorkers would congregate.
Not much has changed over the decades. Well, not a lot. There are many more tourists in these recent years. They join New Yorkers coming to look at the constantly changing garden to see what's new and take in the ambiance.
On August 2018, a UN committee heard that up to one million Uighur Muslims and other Muslims groups were being detained in the western Xinjiang region of China, where they 're said to be undergoing "re-education" programs. As the situation of millions of Chinese Muslims -detained in places that resemble concentration camps- is uncertain, the Council on Foreign Relations organized a lecture on the subject last Thursday.
Invited to participate on the panel were: Ms Gay J. McDoughall, Vice Chair of the Committee on the Elimination of Racial Discrimination, James A. Millward, Professor of Intersocietal History at Georgetown University, and Nury A. Turkel, Chairman of the Board of Directors, Uyghur Human Rights Project. Presiding the panel was Calvin Sims, President and Chief Executive Officer at International House.
It's important to remember that this whole issue with the Uighurs and how they stay into the People's Republic of China goes back to the 18th century, when this territory of Xinjiang was brought under the control of Beijing. Millward said that throughout the 20th century, The PRC never dealt with the issue of ethnic differences. He asserts that since decades, the government of China have been nervous about their own system of dealing with ethnic diversity, which he believes, is superficially modeled after that of the Soviets.
"Particularly since 2008-2009 when there were very serious riots in Tibet and the Uighur region, there were great concerns that maybe the system was actually reinforcing ethnic differences rather than paving the way for a stable future in China", Millward said.
Millward mentions the invention of techniques and technology of state control reaching a new level in China. He said that in 2016 a new high tech surveillance system was put in place in the Xinjiang region to keep Muslims a and their activities under investigation. China's president is really trying to unify Chinese identity, Millward says, and the cultural differences become a serious problem in the minds of Beijing. In this sense, the Ughirs are seen as a source of instability by the Chinese government.
After the panel, many guests wanted to ask a myriad of questions to the panelists. Unfortunately, time went out most questions remained unanswered.
Thursday's event was in commemoration of the late Arthur C. Helton as a Memorial Lecture in his name.
Arthur C. Helton was Director of Peace and Conflict Studies and senior fellow for Refugee Studies and preventive Action at CFR. He died in the 2003 Canal Hotel bombing while he was in Baghdad to assess humanitarian conditions in Iraq.
The New York City Council Committee held a Housing and Buildings hearing on Thursday at City Hall, seeking out necessary information about the operation and safety of all elevators in the city.
The committee is looking to bring up any and all parallels between general public elevators and NYCHA elevators, in order to remedy and eradicate all problems, so as to better service New Yorkers who rely on elevators every day.
Many members of the committee have noticed the many inconsistencies with regulating general public elevators and NYCHA elevators as a whole. There is also a distinct difference in the training between NYCHA workers and those at the Department of Buildings (DOB), which often leaves NYCHA so far down the ladder, in terms of being able to detect and solve problems before and as they happen. There is a desperate need for standardizing the training for NYCHA workers, to match that of the DOB.
Although elevators are put through thorough inspections every single year by the DOB's 51 inspectors, they are still often found to not be running correctly which, at times, leaves passengers injured and afraid.
When someone files a complaint to 3-1-1 for a general public elevator, a DOB inspector is sent out to investigate the issue usually within 24 hours. However, since NYCHA has its own complaint hotline and 3-1-1 is not involved, the DOB is very unlikely to come and it could be days later before the necessary party is finally contacted.
The system that the DOB has in place is not a very trustworthy one for New Yorkers who depend on elevators that are a part of NYCHA since "the city has an understanding with NYCHA that's been in place for quite some time, and that's that NYCHA is responsible for, their own elevators," said Assistant Commissioner of External Affairs Patrick Wehle.
Another issue that needs to be investigated is the extent of verification of the elevator maintenance logs located in private properties, as well as NYCHA.
"Are those logs being verified by DOB?" asked Councilman Mark Gjonaj.
The response was that there is no oversight for private properties, only if there's a complaint that triggers the DOB causing them to have to inspect the location. At this time, they will then verify that the logs are being maintained.
Lastly, being that we've been living in the twenty-first century and are well up to speed on the latest technology, elevator modernization is inevitable. The question that remains is when will it happen.
Throughout the questioning, the assistant commissioner failed to respond with a clear answer several times when the committee addressed possible issues with NYCHA elevators. These questions are to be included in a follow-up hearing in the near future.
We have so many elevators in the city, general public as well as private. "The important thing is that they be maintained properly," said Wehle.


text:
Q: How to extract a number from a two line string in javascript I would like to extract the number "40" from following two lines:
Total Boys:4 (40 min)
Main Students:0 (0 min)

How can I do that using javascript? Thank in advance!

A: Or without a regex
str.split('min').shift().split('(').pop().trim();

FIDDLE

A: Simply use a regular expression:
var str = 'Total Boys:4 (40 min)\nMain Students: 0 (0 min)';
var number = str.match(/\((\d+)/)[1]; // 40

A: Here's a simple regex to pull that value out:
var str = 'Total Boys:4 (40 min)\nMain Students:0 (0 min)';
var regexp = /.*\((\d+) min\)\n.*/;
var matches = regexp.exec(str);
alert('match: ' + matches[1]);

A: Another way of doing it would be simply str.match(/\d+/g)[1] using regex.
DEMO

A: suppose you have your string inside str andyou want to store the number inside n
another approach is this:
var index1,
    index2,
    index3,
    n;

index1 = str.indexOf('Total Boys:', 0);
index2 = str.indexOf('(', index1) + 1;
index3 = str.indexOf(' ', index2);

n = str.substring(index2, index3);

note that this approach will get only the min value of "Total Boys", not "Main Students".
It will work even if you have another similar line before "Total Boys"

redpajama_set_name: RedPajamaStackExchange


text:
Sep 23, 2020 09:10 JST
Source: Eisai
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy
TOKYO, Sep 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced new investigational data from two trials under the LEAP (LEnvatinib And Pembrolizumab) clinical program evaluating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy. In the Phase 2 LEAP-004 trial, the LENVIMA plus KEYTRUDA showed an objective response rate (ORR) of 21.4% (95% confidence interval (CI): 13.9-30.5) in patients with unresectable or advanced melanoma who had previously progressed on an anti-PD-1/PD-L1 therapy. In the Phase 2 LEAP-005 trial, LENVIMA plus KEYTRUDA demonstrated an ORR that ranged from 9.7-32.3% (95% CI: 2.0- 51.4) in previously treated patients with triple-negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (non-microsatellite instability-high [non-MSI-H]/mismatch repair proficient [pMMR]), glioblastoma multiforme (GBM) and biliary tract cancer (BTC). Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
"These new data from our LEAP clinical program show encouraging activity across several aggressive cancer types and expand our knowledge about the potential of KEYTRUDA plus LENVIMA to help a range of patients with these cancers," said Dr. Scot Ebbinghaus, Vice President, Clinical Research, Merck Research Laboratories. "This is the first time that clinical data from two LEAP trials are being presented, reflecting important progress we are making to explore the potential of this combination for patients in need of new options, particularly those with advanced melanoma who have progressed on an anti-PD-1 or PD-L1 therapy."
"We are encouraged by the growing body of research that we have seen to date, now in 13 different cancers, supporting the potential of the LENVIMA plus KEYTRUDA combination, which we're currently evaluating in 19 clinical trials," said Dr. Takashi Owa, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. "These data not only help advance our understanding of the regimen but also fuel our deep-seated determination to work to address the unmet needs of these patients."
Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 (Abstract #LBA44) LEAP-004 (ClinicalTrials.gov, NCT03776136) is a Phase 2, single-arm, open-label trial evaluating LENVIMA in combination with KEYTRUDA in patients with unresectable or advanced melanoma who had progressed on an anti-PD-1/PD-L1 therapy within 12 weeks. Patients were treated with LENVIMA 20 mg orally once daily until unacceptable toxicity or disease progression in combination with KEYTRUDA 200 mg intravenously every three weeks for up to 35 cycles (approximately two years). The primary endpoint is ORR per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR). Secondary endpoints include progression-free survival (PFS) and
duration of response (DOR) per RECIST v1.1 by BICR, overall survival (OS) and safety.
At data cutoff (June 10, 2020), a total of 103 patients were enrolled and treated. With a median duration of follow-up of 12 months (range: 8.7-15.6), LENVIMA plus KEYTRUDA demonstrated an overall ORR by BICR of 21.4% (n=22) (95% CI: 13.9-30.5), with a complete response rate of 1.9% (n=2) and a partial response rate of 19.4% (n=20). In the total study population, the median DOR was 6.3 months (range: 2.1+ to 11.1+), with 72.6% (95% CI: 46.2-87.6) of responses lasting for at least six months. Median PFS was 4.2 months (95% CI: 3.5-6.3), with 73.8% of patients experiencing disease progression or death, and the nine- month PFS rate was 26.2% (95% CI: 17.4-35.9). Median OS was 13.9 months (95% CI: 10.8- not reached [NR]), with death occurring in 44.7% of patients, and the nine-month OS rate was
65.4% (95% CI: 55.2-73.8).
The exploratory analysis showed that specifically, in the 29 patients whose disease progressed after an anti-PD-1/L1 therapy plus an anti-CTLA-4 therapy, the ORR by BICR was 31% (95% CI: 15.3-50.8), with a complete response rate of 3.4% (n=1) and a partial response rate of 27.6% (n=8). Disease control rate (DCR) by BICR in these patients was 62.1% (95% CI: 42.3-79.3). In the total study population, the DCR by BICR was 65% (95% CI: 55.0-74.2).
Treatment-related adverse events (TRAEs) led to discontinuation of LENVIMA and/or KEYTRUDA in 7.8% of patients. Grade 3-5 TRAEs occurred in 44.7% of patients (Grade 3: 39.8%; Grade 4: 3.9%; Grade 5: 1.0%), and serious TRAEs occurred in 18.4% of patients. The most common TRAEs of any grade occurring in at least 30% of the overall study population, were hypertension (56.3%), diarrhea (35.9%) nausea (34.0%), hypothyroidism (33.0%) and decreased appetite (31.1%).
LEAP-005: Phase 2 Study of Lenvatinib Plus Pembrolizumab in Patients (Pts) With Previously Treated Advanced Solid Tumors (Abstract #LBA41)
LEAP-005 (ClinicalTrials.gov, NCT03797326) is a Phase 2, single-arm, open-label trial evaluating LENVIMA in combination with KEYTRUDA in patients with select previously treated advanced solid tumors. The study cohorts are TNBC, ovarian cancer, gastric cancer, colorectal cancer (non-MSI-H/pMMR), GBM and BTC. Patients have treated with LENVIMA 20 mg orally once daily until unacceptable toxicity or disease progression in combination with KEYTRUDA 200 mg intravenously every three weeks for up to 35 cycles (approximately two years). The primary endpoints are ORR per RECIST v1.1 as assessed by BICR or Response Assessment in Neuro-Oncology (RANO) criteria (for GBM only) as assessed by BICR, and safety. Secondary endpoints include DCR per RECIST v1.1 by BICR or RANO (for GBM only) by BICR, DOR per RECIST v1.1 by BICR or RANO (for GBM only) by BICR, PFS per RECIST v1.1 by BICR or RANO (for GBM only) by BICR, and OS.
The most common TRAEs of any grade occurring in at least 20% of the overall study population were hypertension (39.0%), fatigue (29.4%), diarrhea (26.7%), decreased appetite (25.1%), hypothyroidism (27.8%) and nausea (21.9%). Based on these initial results, the trial will expand to enroll approximately 100 patients in each cohort.
About LENVIMA (lenvatinib) Capsules
LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRalpha), KIT, and RET. In syngeneic mouse tumor models, lenvatinib decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. Currently, LENVIMA has been approved for monotherapy as a treatment for thyroid cancer in over 65 countries including Japan, the United States, in Europe, and in Asia, and for unresectable hepatocellular carcinoma in over 65 countries including Japan, the United States, in Europe, China and in Asia. Additionally, it is also approved in combination with everolimus as a treatment for renal cell carcinoma following prior antiangiogenic therapy in over 55 countries, including the United States, in Europe (where it was launched under the brand name Kisplyx for renal cell carcinoma) and in Asia. In addition, it is approved in combination with KEYTRUDA as a treatment for patients with advanced endometrial cancer that is not microsatellite instability- high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation in countries including the United States, Australia, and Canada. Continued approval for this indication is contingent upon verification and description of clinical benefit in the confirmatory trials.
About KEYTRUDA (pembrolizumab) Injection
KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Merck & Co., Inc., Kenilworth, N.J., U.S.A. has the industry's largest immuno-oncology clinical research program. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration
In March 2018, Eisai and Merck, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA.
In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer and triple-negative breast cancer) across 19 clinical trials.
Eisai's Focus on Cancer
Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from Halaven (Eribulin mesylate) and Lenvima) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can become a frontrunner in oncology. Eisai will discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.
About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.
For more information about Eisai, please visit www.eisai.com (for global), us.eisai.com (for U.S.) or www.eisai.eu (for Europe, Middle East, Africa), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S.).
Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s Focus on Cancer
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck & Co., Inc., Kenilworth, N.J., U.S.A., the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck & Co., Inc., Kenilworth, N.J., U.S.A. is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
About Merck & Co., Inc., Kenilworth, N.J., U.S.A.
For more than 125 years, Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD
outside of the United States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world's most challenging diseases in pursuit of our
mission to save and improve lives. We demonstrate our commitment to patients and
population health by increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck & Co., Inc., Kenilworth, N.J., U.S.A. the forefront of research to prevent and treat diseases that threaten people and animals -- continues to be at the
including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases -- as we aspire to be the premier research-intensive biopharmaceutical company in the
world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Eisai Co., Ltd.
+81-(0)3-3817-5120
Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Pamela Eisele: (267) 305-3558
Rebecca Newberry: (484) 678-2952
Related Press Release
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

redpajama_set_name: RedPajamaCommonCrawl


text:
Q: How to print a horizontal line that is as long as the user inputs it If I want to create a horizontal line of asterisks that is decided by the user, how would I do that? For example, I want to print a line that shows
01:...........(custom number)
02:........(custom number)
03:.......(custom number)
etc...
In this case I am taking the sales number from a file and printing a number of asterisks that represent the companies earnings in hundreds on any given day. In case that changes anything.
Sorry, edit: This is in python

A: Use:
print '*' * n

where n is the number of asterisks you wish to display.
Here is a more complete example:
lens = [3, 5, 10, 1]
for i, l in enumerate(lens):
  print '%02d:%s' % (i + 1, '*' * l)

This displays:
01:***
02:*****
03:**********
04:*

A: The following answer only applies if you want to plot a horizontal line in Jupyter Lab / Jupyter Notebook:
from IPython.display import Markdown, display
display(Markdown('---'))

Looks like:

A: Are you trying to multiply it by the length of the input? if so you can do the following:
x=raw_input("number/message: ")
y="*"*len(x)
print y

However, if you are looking to get x amount of "*" to a number you can do:
x=int(raw_input("number: "))
y="*"*x
print y


Home/Academics/Degrees and Programs/Cross-Cultural and Global Studies M.A.
Cross-Cultural and Global Studies M.A.
University of Houston-Clear Lake's classes use an interdisciplinary approach to consider experiences and inequalities based on race, gender, ethnicity, class, sexuality and nationality. Through the lenses of anthropology, history, geography, literature and sociology, you'll gain new insight into the complexities of national and global culture.
As a cross-cultural and global studies student in UHCL's College of Human Sciences and Humanities, you'll use a broad range of theories and methodological approaches to explore today's pressing issues. The program offers concentrations in urban studies; religions in dialogue; women, gender and sexuality; and Latin American studies. Led by our passionate faculty, you'll gain both theoretical and practical training as you dig deep into complex issues. Graduates of this program have gone on to successful careers in law, education, non-profit agencies and religious organizations. You may also partake in one of several study abroad opportunities, to such places as Egypt, Turkey or Oman. You will finish up with a capstone experience that is either practically oriented in an internship or focused on conducting original research in a thesis or a project.


text:
Home / Bangladesh / Counter Terrorism / Islamic State / Opinion / South Asia / Terrorism / OPINION | From Dhaka to Singapore: The Growing Involvement of Bangladesh in the "World of Global Jihad"
OPINION | From Dhaka to Singapore: The Growing Involvement of Bangladesh in the "World of Global Jihad"
IndraStra Global Tuesday, January 26, 2016 Bangladesh , Counter Terrorism , Islamic State , Opinion , South Asia , Terrorism Edit
By Dr. Siegfried O. Wolf
Against the persistently recurrent official statements that Bangladesh has no links with internationally acting terrorist organisations like Islamic State (IS) or al-Qaeda, there are more and more indications how deeply the Islamic fundamentalists of the South Asian country are involved in the "world of the global jihad".
One of the latest examples of such is 2015 detention of 14 Bangladeshi nationals, who were part of a group of 26 construction workers in Singapore. The authorities of the city-state found clear evidence that these Bangladeshi nationals were supporting armed jihadist ideology of al-Qaeda and the Islamic State (IS), and planned to take part in extremist activities elsewhere, and also shared jihadist material. Already in 2013, the 14 formed a growing terrorist group but not in order to carry out attacks on the island but to 'wage holy war' oversea, especially in their home country. The arrest of these radical Islamists under the Internal Security Act (ISA) is a decisive moment since it was the first time that a jihadist terror cell comprising foreigners has been uncovered in Singapore. Furthermore, there is also a compounded threat that the South East Asian State could also move into the focus of terrorists as a target.
However, after interrogation the Dhaka Metropolitan Police (DMP) stated that the 14 detainees have links to the domestic radical group Ansarullah Bangla Team (ABT, also known as Ansar Bangla). ABT, an Islamist group which is banned in Bangladesh under Article 18 of the anti-terrorism act, is known for its attempts to suppress freedom of speech in general and independent, liberal and secular thinking in particular. In result, each academic and independent intellectual, blogger or cultural personality who poses a threat to the fundamentalist Islamic teachings and lifestyle is considered a potential target of ABT.
One of their major aims of ABT is to promote their adapted notion of Islam and thus, act to silence any critics of extremist religious doctrines, organized Islam, and the intolerance of Islamist radicals. The spiritual leader of ABT Jashim Uddin Rahmani, a fanatic cleric was jailed in December 2015 for demanding the killing of Ahmed Rajib Haider. Furthermore, they published a 'global hitlist' of bloggers, activists, writers, and cultural figures claiming that they will get murdered if they are not following the demands and lines of ABT. As such, ABT is responsible for threatening and attacking of numerous secular thinkers as well as openly abetting the killing of them. There are also reports that Shiites and Sufi Muslims as well as several foreigners have been killed too. In this context, it is interesting to mention that not only ABT and international jihadists networks are linked but that ABT is also actively recruiting Bangladeshi college students for the IS. As the latter one claimed responsibility for the killing of several foreigners. Here, a significant query calls for- what is the Bangladeshi state doing about this and why it seems that the authorities failed to tackle the issue of the Islamic fundamentalism and increasing international linkages?
Generally, one can state that the country's political establishment still seems to be ignorant when it comes to the realization of the full threat of Islamic fundamentalism. The way how authorities and analysts are downplaying or ignoring the growing influence of terror groups like ABT and their links with international jihadist networks of Islamic State and Al-Qaeda (especially Al Qaeda in the Indian Subcontinent, or AQIS) is perturbing since it will open further space for the promotion and entrenchment of a fundamentalist ethos in Bangladesh. Just banning militant religious organisation like ATB is not enough. The country needs a comprehensive concept against religious fundamentalism accompanied by a coherent and stringent counter-terrorism strategy. Until now, the few measures carried out by the current government to contain the radical (militant) Islamist threats remain ineffective, especially if one looks at the mobilising capacities of the Islamists and the domestic and international activities of 'officially' banned organisations. Most importantly, the unprofessional actions against radical Islamist organisations did not have the desired effects. Instead of eradicating the threat, radical Islamists were able to portray themselves as being unjustly persecuted.
The ban of the JI is such an example. Bangladesh's decision-makers did not understand that the costs of ignoring Jihadism are much higher than narrow political ends and electoral benefits from radicalized sections of the country's electorate. Bangladesh should not do the same mistake like Pakistan, allowing or even encouraging domestic militancy and international terrorist groups to use Bangladeshi territory as a launch pad for Jihadist activities. Therefore, ABT stands not only for Bangladesh's growing involvement in the international Jihadist networks, as the Singapore presence of ABT clearly emphasizes the embeddedness of this group in the 'world of the global Jihad'. But what is to note is the new assertiveness, self-confidence and self-perception of Bangladesh's jihadists who find an expression in the willingness to operate as a group independently overseas. This marks a decisive departure from activities of former generations of militant Islamic fundamentalists, who went abroad fighting under the banner of another jihadist group , such as the Mujahedeen or Taliban in Afghanistan.
To sum up, the presence of ABT members in Singapore can be seen as an indication: First, that ABT is looking beyond Bangladesh borders to promote and participate in Jihadi activities, not just limited to South- but also in South East Asia; secondly, that they are trying to build-up their own international network to carry out Jihadi activities; thirdly, they are operating independently of the financial and logistic support of worldwide acting terror groups like IS or al-Qaeda. Therefore, the diktat of the moment is that the government of Bangladesh with its security agencies must work out a concrete and comprehensive strategy to counter the domestic and global Jihadist threats. If not, ABT and other Islamist group will not only threaten Bangladesh but will lose the country's very essence of democracy, secularism, and tolerance.
Dr. Siegfried O. Wolf, is Senior Researcher (member) at the South Asia Institute (SAI), Heidelberg University, and Director of Research at SADF (Coordinator : Democracy Research Program). He was educated at the SAI and Institute of Political Science (IPW) in Heidelberg. Additionally he is a visiting fellow at the National University of Science and Technology (NUST, Islamabad), affiliated researcher at the Pakistan Security Research Unit (PSRU, Durham University), and a former research fellow at IPW and Centre de Sciences Humaines (New Delhi, India).
He is the co-author of 'A Political and Economic Dictionary of South Asia' (Routledge; London 2006), co-editor of 'Politics in South Asia. Culture, Rationality and Conceptual Flow' (Springer: Heidelberg, 2015), 'The Merits of Regionalisation. The Case of South Asia' (Springer: Heidelberg, 2014) and 'State and Foreign Policy in South Asia' (Sanskriti: 2010), and Deputy Editor of the 'Heidelberg Papers in South Asian and Comparative Politics' (HPSACP). Furthermore, he has worked as a consultant for the Federal Ministry for Economic Cooperation and Development (BMZ), Germany, and is member of the external group of the Afghanistan-Pakistan Task Force, Federal Foreign Office, Germany.
Cite This Article:
Wolf, Siegfried O."OPINION | From Dhaka to Singapore: The Growing Involvement of Bangladesh in the "World of Global Jihad"" IndraStra Global 02, no. 01 (2016): 0083. http://www.indrastra.com/2016/01/OPINION-From-Dhaka-to-Singapore-002-01-2016-0083.html | ISSN 2381-3652


3.1 - Take the course!
Want help writing your four UC personal insight questions?
How do I know if my topics are good ones?
How do I stand out when answering the UC prompts?
What does a great UC application prompt look like?
LOOKING FOR A MORE COMPLETE GUIDE TO ANSWERING THE NEW UNIVERSITY OF CALIFORNIA PROMPTS?
Take my How to Answer the New UC Application Prompts video course.


The ITT Elektronik Experimenter kit seems to be used at schools. It is a thorough step by step introduction to electronics in an typical school style: some theory, an assignment, an experiment with the components and a form to be filled in and judged by the teacher.
The logo on the wooden box.
The kit has large experimenters board, a transformer and a power supply.
Components are placed on little boards with pins on the botton to stick in the board, and pins on the top for the conenctions between the components.
Connections between the component boards are made with cables.
The components range from the common resistors, capacitors, diodes and transitors to even a opamp (a 741). Some boards are not yet populated, to enable expansion.
Above the front of the manul, below the list of components.


text:
Megaselia excisoides är en tvåvingeart som beskrevs av Rudolf Beyer 1966. Megaselia excisoides ingår i släktet Megaselia och familjen puckelflugor. Inga underarter finns listade i Catalogue of Life.

Källor

Externa länkar

Puckelflugor
excisoides

redpajama_set_name: RedPajamaWikipedia


Sports and athletics are an important part of our society. Sport managers are required to plan, organize, promote and direct sporting activities. Our Sports Management degree in Minnesota is designed for students who want to gain the skills and preparation needed to fill these roles across the U.S. and internationally as well.
Students in the Sports Management program will earn a Bachelor of Science degree and gain a solid understanding of the social, ethical, economic, legal and political factors that impact the management and administration of sport organizations. Sports Management majors will learn about finance, law, organization management, personnel and marketing.
Students have the opportunity to be involved in the intercollegiate athletic department, the intramural program and the professional sport arena. An internship, which offers students the opportunity to practice what has been learned in their courses and to further their learning, is a requirement for graduation.
Students apply for departmental acceptance during their sophomore year spring semester or their junior year fall semester. A minimum 2.0 cumulative GPA and completion of half of the Christian Service requirements are required for departmental admission in the Sport Management major.


text:
Glycine — марка швейцарских часов.

Основана в 1914 году Юджином Мейланом с производством в городе Бьен (Швейцария).

Юджин Мейлан создал точный миниатюрный механизм для женских часов, тем самым предложив рынку дамские часы, которые часто имели корпуса из золота и платины или украшались бриллиантами.

В 1931 году Мейлан представил высокоточный механизм с автоматическим подзаводом. Единичные экземпляры этих часов, названных Glycine Eugene Meylan SA с автоматическим подзаводом, изредка встречаются на специализированных аукционах и являются предметом гордости коллекционеров.

1934 год стал знаменателен для Glycine запуском производства хронометров.

Glycine получила известность в начале 1950-х годов после выпуска модели «Airman» с 24-часовым циферблатом, которая пользовалась популярностью у пилотов как военной, так гражданской авиации. Airman носили многие пилоты ВВС США во время войны во Вьетнаме. Несколько вариантов этой модели Glycine продолжает выпускать до настоящего времени. Продукция Glycine также включают серии Incursore, KMU 48, Combat и Lagunare.

Ссылки

 Официальный сайт Glycine Watch SA

Организации по алфавиту
Компании Швейцарии
Швейцарские часы
Производители часов Швейцарии


Musings - Mark Rindflesh's Portfolio - Why I chose Format to rebuild my website.
Why I chose Format to rebuild my website.
well as building the site. Thus it's up and running now.
thinking about building or rebuilding a new website.


The latest developments in the investigation is raising concerns among Samsung's affiliates regarding its impact on the nation's economy.
To take a closer look at the possible repercussions reaching not just the corporate giant but the President herself, we turn to our Lee Unshin.
Samsung Electronics, the world's number-one smartphone maker, accounts for nearly 20-percent of Korea's gross domestic product.
So the independent counsel's request for an arrest warrant for vice chairman Lee Jae-yong, who's expected to one day take over formal leadership of the conglomerate,... came as unsettling news for many.
An official from the Korea Chamber of Commerce and Industry, along with representatives of some Samsung affiliates, have urged the authorities to weigh the decision over Lee's arrest carefully,... claiming that his detention could have a major impact on the Korean economy.
Though the Seoul court won't announce a decision until Wednesday,... experts seem to be siding with the prosecution.
"Considering how the case has unfolded so far, the arrest warrant will be issued... unless the court decides to give Lee 'special treatment.' And furthermore, Samsung as a company is solid enough in terms of its structure,... so while Lee's detention could have a short-term effect, it won't be the determining factor in the company's future or the overall economy."
The accusations of bribery stem from payments Samsung made to entities controlled by Choi Soon-sil in return for help getting a controversial merger approved, which helped vice chairman Lee secure his future leadership of the group.
If a formal charge of bribery is brought against the vice chairman, it could also implicate President Park Geun-hye and her confidante Choi Soon-sil, both of whom are said to have benefited from bribery but have denied any wrongdoing with respect to the influence-peddling scandal.
"If Lee is arrested, it indicates the bribery charges are valid. And as one of the figures believed to have benefited from the bribery, the president will also face questions."


text:
Кухар — професія.

Кухар — українське і польське прізвище.

 Кухар Андрій Анатолійович (1987—2016) — капітан Збройних сил України, учасник російсько-української війни.
 Кухар Роман Михайлович (псевдонім Володимир Р.) (1920—2007) — український прозаїк, поет, літературознавець, перекладач, публіцист, співак. Професор Канзаського університету (штат Канзас, США).
 Кухар Валерій Павлович (1942—2017) — доктор хімічних наук, професор, академік НАН України.
 Вацлав Кухар (1897—1981) — польський спортсмен.
 Тадеуш Кухар (1891—1966) — польський спортсмен і футбольний тренер.
 Марина Кухар — українська телеведуча.

Українські прізвища
Польські прізвища


Hugs The Foot And Keeps It Locked Down.
Ensures Comfort For Barefoot Usage.
Provides A Snug, Comfortable Fit.
Offers Optimum Fit And Comfort.
Brings The Runner Up Onto Their Toes.
8Mm. For The Best In Torsion And Propulsion.


text:
Home » Health News » NYPD Blue and Deadwood Creator David Milch Reveals He Has Been Diagnosed with Alzheimer's Disease
NYPD Blue and Deadwood Creator David Milch Reveals He Has Been Diagnosed with Alzheimer's Disease
David Milch, the creator of NYPD Blue and Deadwood, is opening up about his health.
The longtime producer, 74, recently spoke with Vulture, where he revealed that he was diagnosed with Alzheimer's disease about a year ago.
"As best I understand it, which is minimally, I have a deterioration in the organization of my brain," he told the outlet in an interview published Tuesday. "And it's progressive. And in some ways discouraging. In more than some ways — in every way I can think of."
Milch, who was the mastermind behind ABC's long-running police drama for 12 years, as well as HBO's Western series for two years, said that he first discovered that something was wrong about five years ago when he began to notice changes in his behavior and focus.
Aside from his memory not working as sharply as it once did, Milch, his family, and friends started to realize how frequently his "short temper" would get the best of him.
RELATED: NYPD Blue Creator David Milch Lost $100 Million Fortune to Gambling Addiction
His work also struggled and Milch often found himself dealing with uncertainties, hesitations, and "a growing incapacity" to write.
"I became more and more of an acquired taste," Milch, who previously struggled with a gambling addiction, recalled to the outlet.
It wasn't until 2018, however, that the producer decided to finally receive a brain scan, which revealed he had Alzheimer's.
The diagnosis seemed to click for Milch, as all of the signs he had been experiencing were similar to his own father's, who he believed likely also suffered from the illness.
"That was a while ago, and the diagnosis was not as sophisticated or specific, but in retrospect, he exhibited all the symptoms of the illness," Milch told Vulture.
RELATED: Hal Ketchum, 66, Diagnosed with Alzheimer's and Dementia: 'It's an Exhausting, Confusing Illness'
Still, the diagnosis hasn't stopped Milch from doing what he loves and staying busy with work. Years after wrapping up Deadwood on HBO in 2006, Milch decided to return to the series and wrote a television movie for the network.
Deadwood: The Movie, which is set to premiere on May 31, will be a continuation of the original television series and feature most of the original cast, including Ian McShane and Timothy Olyphant.
The network and his colleagues on the film have been particularly supportive of Milch in the wake of his diagnosis, though the cast and crew do not publicly discuss it, Milch said.
In the wake of Milch's decision to go public with his diagnosis, HBO issued a statement and announced their support for him.
"We treasure our relationship with David Milch, a beloved and long-standing member of the HBO family," a rep from the network told Deadline. "We honor David's privacy and stand by his side in every way as he faces this challenge."
Representatives at HBO did not immediately respond to PEOPLE's request for comment.
Jameela Jamil Reveals She Has Rare Syndrome That Causes Loose Skin and Extremely Flexible Joints
My 600-Lb. Life Star Sean Milliken Is Dead at Age 29
Selma Blair Opens Up in First Interview Since MS Revelation: I 'Cried with Relief' After Diagnosis
Ankylosing Spondylitis Affects Millions Including Imagine Dragons' Dan Reynolds — What Is It?
Reese Witherspoon Loves Jameela Jamil's Talks on Body Positivity: 'So Great and Inspiring'
Vitamin B12 deficiency symptoms: This sign when you walk could signal the condition
Turns Out Your Favourite Workout Could Be Making You Constipated


text:
Review: THE WRITER at Q Theatre
THE WRITER is gripping, fervid and powerful.
by Glenda Pearce Sep. 04, 2022
THE WRITER is an emotionally rich, eloquent and engaging play that surprises. This is an adult play that addresses creativity, gender inequalities and power, particularly in the theatre setting: "You get to make the world and I get to live in it." As an audience, you are asked to consider your ethics, your values, your understanding of the creative spirit and the creative process. Above all else, THE WRITER is gripping, fervid and powerful.
The play's structure is episodic, multi-layered, and packed with nuances. We are observing, it seems, the creative process of writing and workshopping a play for production. Each of the scenes brings new perspectives and truths: " Writing is about truth", says the Writer later, "Theatre is sacred and should be used to heal people not get off on. Theatre shouldn't be pretence - it should be real and the actors should bring out the truth to the audience." This psychological and emotional truth is created superbly with outstanding performances by the experienced and accomplished cast: Sophie Henderson (the Writer), Stephen Lovatt (the Director), Matt Whelan (the Male Actor) and Ash Williams (the Young Woman).
Adeptly directed with an artistic and creative eye by Sophie Roberts, THE WRITER is provocative and thought-provoking. In the opening moments, the Young Woman moves from the audience to the stage and confronts the Male Actor. She is angry that the play's action is so unrealistic and sexualised: "silent women in hot pants."The conversation is realistic, natural and quick-paced. She wants "the world to change shape" through her writing. She will have a voice. "Writing is just speaking but with passion." We are quickly drawn into the argument that develops when the Young Woman reveals the connection they have had six years earlier - when the opportunity for her to work as a writer came enmeshed with sexual favours.
This is a play that addresses power - commercial and sexual. From episode two, the Q and A which appears to directly involve us, the audience, we see the clash between "self-expression and self-indulgence". The Writer argues that "artists have to feel safe in order to make art" and the Director says that "money fosters confidence, art is confidence."
We see how the Writer's creative process and artistic temperament, so vital to her joy and happiness, is constrained by the men in her life: the Director who wants commercial success above all else, the male partner who wants money (and sex) rather than her happiness and creative choice.
The Q and A, and later episodes, illustrate how the female writer gets painfully shut down by the men with the money: "letting producers distort your truth is like your unborn children b given plastic surgery". In particular, the motif of the baby crying is a dominant force in the play's construction. A baby is a creation, and a symbol of innocence, purity, new beginnings, inner potential, rebirth. When we hear the sounds of the baby's cries, we are asked to consider - and connect to - what the Writer is experiencing. What part of her "inner potential" is not being recognised? What part of her creative self is not being nurtured? We feel her pain.
Well-designed and executed sound (Paloma Schneiderman) and artistic lighting (Rachel Marlow) integrate well with the play's intent. The reality of the play process is supported with "working" stage elements - we can see the stage crew dressing the actors and providing props (including a real baby), clearing the scenes, and moving the set. The Director watches the action from downstage right - ensuring the Writer always feels his dominance.
THE WRITER is the Writer's story above all else. Sophie Henderson's truthful portrayal manages to capture the Writer's desire to have unburdened joy, to just be, as well as communicating the crushing challenges to her creative spirit.
This is a play for the artists and the creators, theatre-makers and theatre-goers. The play definitely connected with many in the audience. It's an authentic picture of many theatrical and political conversations today and definitely worth seeing.
On until 18 September at Q Theatre. Bookings through nz.patronbase.com or the theatre.
Related Stories View More New Zealand Stories
Review: ANTHONY AND CLEOPATRA at Shoreside Theatre, Pumphouse Theatre
What did our critic think of ANTHONY AND CLEOPATRA at Shoreside Theatre, Pumphouse Theatre?
YES YES YES Comes to ASB Waterfront Theatre Next Month
Yes Yes Yes comes to ASB Waterfront Theatre in 2023. Performances will run 28 February - 1 March.
THE HEARTBREAK CHOIR Comes to ASB Waterfront Theatre Next Month
THE HEARTBREAK CHOIR comes to ASB Waterfront Theatre next month. Performances run 14 February - 4 March.
SANDSONG Comes to ASB Waterfront Theatre Next Year
An Australian national treasure, Bangarra is one of the most respected First Nations companies on the planet.
From This Author - Glenda Pearce
Glenda Pearce is a professional speaker on # dynamic speaking #bodyworks #body communication # effective communication . She is also a specialist professional effective speaking coac... (read more about this author)
Review: DI AND VIV AND ROSE at The Pumphouse Theatre, Takapuna, Auckland
What did our critic think of DI AND VIV AND ROSE at THE PUMPHOUSE Theatre, Takapuna, Auckland?Don't we all hunger for human connection? Love? Support? Laughter? Directed superbly, with exquisite attention to detail, by Stephanie McKellar- Smith, the action of this emotionally-charged play centres on the powerful bond between three women. The cast (Lisa Chappell, Eilish Moran, Jodie Dorday) is exceptional and there isn't a moment when we are not captivated. Enacted with psychological, physical and emotional truth - faces, voices and movement ensure that right from the outset, we have a clear indication of the personality, values, attitudes and ambitions of the three "girls". The 1980s was indeed a time of shift
Review: THE WHALE RIDER at The Pumphouse Theatre, Takapuna, Auckland
What did our critic think of THE WHALE RIDER at The Pumphouse Theatre, Takapuna, Auckland?
Review: THE WASP at Q Theatre, Auckland
What did our critic think of THE WASP at Q Theatre, Auckland?
Review: SHEPHERD at Howick Little Theatre
What did our critic think of SHEPHERD at HOWICK LITTLE THEATRE?
New Zealand SHOWS
ASB Waterfront Theatre (6/13-7/02)
Witi's Wāhine
Basmati Bitch
Q Theatre (7/11-7/23)
Auckland Theatre Company (6/12-7/01)
Things That Matter
The Heartbreak Choir
Magic Men Australia
Napier Municipal Theatre (6/02-6/02)
ASB Waterfront Theatre (9/19-10/08)
Auckland Theatre Company (9/19-10/07)
Get New Zealand News